Navigation Links
Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Date:11/2/2011

pectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulus' management, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus', Alnylam's, and Isis' programs are described in additional detail in Alnylam's and Isis' annual reports on Form 10-K for the year ended December 31, 2010, and its most recent quarterly report on Form 10-Q.  Copies of these and other documents are available from Alnylam or Isis.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
4. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 For the ... Quality of Life Throughout Europe, the Middle ... Astellas Pharma EMEA is celebrating its 10 ... through the historic merger of Japanese pharmaceutical companies Yamanouchi ... committed to turning science into value for patients through ...
(Date:5/22/2015)... May 22, 2015  Research and Benchmarking firm, ... Medical Affairs Roundtable on Thursday, May ... virtual roundtable to discuss "Medical Affairs, Role in ... Practices, Medical Affairs Consortium provides Medical Affairs leaders ... key challenges they face. The consortium has developed ...
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
Breaking Medicine Technology:Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... The Pittsburgh Life Sciences Greenhouse (PLSG), ... formation and business growth programs to the region,s ... President and Chief Executive Officer, John W. ... signing an agreement with Ortho-McNeil-Janssen Pharmaceuticals, a Johnson ...
... Pa. , June 22 TheraQuest Biosciences, Inc., a ... TheraQuest also announced the launch of its new corporate website at ... , ... a careful strategic review of our pipeline, we have realigned our ...
Cached Medicine Technology:The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy 2TheraQuest Unveils New Pain Management Product Pipeline 2TheraQuest Unveils New Pain Management Product Pipeline 3TheraQuest Unveils New Pain Management Product Pipeline 4TheraQuest Unveils New Pain Management Product Pipeline 5
(Date:5/26/2015)... May 26, 2015 Hexagon Geospatial is ... Defence and Space in a new content-sharing program that ... for use in the development of smart applications. ... this partnership combines optical satellite data from Airbus Defence ... tear down the walls between geospatial content, software and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 i2i Systems, ... solutions for more than 15 years, has earned 2014 ... Committee for Quality Assurance (NCQA) for its flagship product ... are proud of the work we have done to ... grateful for the acknowledgement from NCQA once again,” said ...
(Date:5/26/2015)... 2015 Scientists at the University of ... help advanced mesothelioma patients benefit from immunotherapy; surgery may ... article on the new research. Click here to ... of thoracic surgery and pulmonology theorized that, because large ... system attack, immunotherapy drugs might work better if the ...
(Date:5/26/2015)... 2015 ProTrailer Network is a new ... Pro X . This Effect includes 30 all ... styled text. , ProTrailer Network allows users to ... can easily complement any form of media project. FCPX ... can make professional looking openers. , ProTrailer Network includes ...
(Date:5/26/2015)... 2015 Learning ZoneXpress is excited to ... Education Cards . These cards have been specifically designed ... simple, easy-to-read text, these new educational resources are extremely ... practical nutrition tips and suggestions to clients and provide ... , + MyPlate: Eat for a Healthy Baby Pregnancy ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 2Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2
... a forewarning from severe periodontal disease than non-diabetic pregnant ... periodontology.// ,Researchers from the University of Iowa Colleges ... and 20 non-diabetic women in their 20-39th week of ... the control of diabetes. They found the diabetics flaunted ...
... men who eat up tomato products more than twice ... prostate cancer. Consuming cooked tomatoes was particularly beneficial, according ... sauce, ketchup and other tomato-based foods lowered the prostate ... ,Dr. Edward Giovannucci of Brigham and Women's Hospital and ...
... transplant patients contracted a dangerous parasitic disease from their ... women died, but only one recovered after antibiotic treatment.// ... Disease Control and Prevention turned up 26 bacterial infections ... in the United States. ,This shows that the ...
... medications than smokers, as the extra weight poses them ... the nation's principal cause of preventable deaths, the surgeon ... ,For a more precise look at the ... from two national health surveys to estimate inpatient and ...
... Getting cold out of doors condenses the blood and increases ... of University of Texas, it has been found that too ... - in Britain. He believes that cold temperatures alter the ... raises the risk of clotting and heart attack. ...
... gender were among the best indicators of how you might ... state-by-state study of prescription drug use, where you live also ... you use. // ,According to the study, the percentage ... ranged from a high of 71 percent in Kansas to ...
Cached Medicine News:Health News:Prescription Drug Use Varies Widely Between States 2
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
... way to lift the heart - Guidant's ... 3. The XPOSE 3 is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... The CLEARGLIDE Optical Vessel Dissector has application ... operative cavity in the extraperitoneal spaces such ... The device may be used in surgical ... EVH system enables harvesting of a quality ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Medicine Products: